Monday, August 8, 2011
Allos Therapeutics Inc., of Westminster, Colo., reported that second quarter net sales of peripheral T-cell lymphoma drug Folotyn (pralatrexate) increased 39 percent to $11 million compared to $7.9 million for the same quarter in 2010.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.